Clinical study for the efficacy of mesalazine for the treatment of small bowel injury caused by non-steroidal anti-inflammatory drugs(NSAIDs).
- Conditions
- Patients with rheumatoid arthritis with anemia taking NSAIDs
- Registration Number
- JPRN-UMIN000005362
- Lead Sponsor
- Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 13
Not provided
Patients treated with mesalazine or salicylic acid 2 weeks proior to the entry of this study. Patients with escalating the dose of anti-rheumatoid arthritis drugs such as aspirins or proton pump inhitors. Patients took gastroprotective agents such as rebamipide, ecabet sodium, misoprostol. Patients being treated with high-dose corticosteroids (more than 15 mg/day of prednisolone. Patients treated with biologics 90 days prior to the entry of this study. Patients who were allergic to or suffered from side effects by mesalazine of salicylic acids. Patients incapable of swallowing capsule endoscopy. Patients suspicious of intestinal strictures. Patients with malignancies. Pregnancy or possible pregnancy. Patients with side effects by other previous clinical studies. Patients who were considered unsuitable for this study by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Endoscopic findings by capsule endoscopy. Side effects due to the mesalazine treatment.
- Secondary Outcome Measures
Name Time Method Patients' joint and abdominal symptoms. Serum cytokines. Fecal calprotectin